Pricey sickle cell treatments raise daunting new challenges for Medicaid programs; European regulators tout their accomplishments against pharma’s anticompetitive practices

Taking stock of the drug industry, from the lab to the medicine chest

January 29, 2024 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Illustration: Christine Kao/STAT; Courtesy: Kourtney Cunningham STAT+ | Pricey sickle cell treatments raise daunting new challenges for Medicaid programs Across the U.S., policymakers, government officials, and patients are uncertain how Medicaid will cope with the added budget strain. By Ed Silverman STAT+ | European regulators tout their accomplishments against pharma's anticompetitive practices Between 2018 and 2022, European regulators adopted 26 decisions concerning anti-competitive practices by drug companies. By Ed Silverman Opinion: Which country has the best health care? That's the wrong question We should spend less time debating which model is ideal and more time learning from the nearly 200 natural experiments around the world. By Irene Papanicolas Adobe STAT+ | Cognito raises $35 million for Alzheimer's treatment device, touts benefits compared to drugs Instead of drugs, Cognito treats Alzheimer's with a headset utilizing sound and gamma frequency light. Trials are expected to close in 2025. By Mario Aguilar

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2024, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser